The China National Medical Products Administration approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
FDA approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor-mutated non-small cell lung cancer.
